Suppr超能文献

Ki-67在上尿路高级别尿路上皮癌患者中预测价值的多机构验证

Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract.

作者信息

Krabbe Laura-Maria, Bagrodia Aditya, Haddad Ahmed Q, Kapur Payal, Khalil Dina, Hynan Linda S, Wood Christopher G, Karam Jose A, Weizer Alon Z, Raman Jay D, Remzi Mesut, Rioux-Leclercq Nathalie, Haitel Andrea, Roscigno Marco, Bolenz Christian, Bensalah Karim, Sagalowsky Arthur I, Shariat Shahrokh F, Lotan Yair, Margulis Vitaly

机构信息

Department of Urology, University of Texas Medical Center, Dallas, Texas; Department of Urology, University of Muenster Medical Center, Muenster, Germany.

Department of Urology, University of Texas Medical Center, Dallas, Texas.

出版信息

J Urol. 2015 May;193(5):1486-93. doi: 10.1016/j.juro.2014.11.007. Epub 2014 Nov 11.

Abstract

PURPOSE

We validate the independent predictive value of Ki-67 in patients with high grade upper tract urothelial carcinoma.

MATERIALS AND METHODS

A total of 475 patients from the international Upper Tract Urothelial Carcinoma Collaboration who underwent extirpative surgery for high grade upper tract urothelial carcinoma were included in this study. Immunohistochemical staining for Ki-67 was performed on tissue microarray formed from this patient cohort. Ki-67 expression was assessed in a semiquantitative fashion and considered over expressed at a cutoff of 20%. Multivariate analyses were performed to assess independent predictors of oncologic outcomes and Harrell's C indices were calculated for predictive models.

RESULTS

The median age of the cohort was 69.7 years and 55.2% of patients were male. Ki-67 was over expressed in 25.9% of patients. Ki-67 over expression was significantly associated with ureteral tumor location, higher pT-stage, lymphovascular invasion, sessile tumor architecture, tumor necrosis, concomitant carcinoma in situ and regional lymph node metastases. On Kaplan-Meier analyses over expressed Ki-67 was associated with worse recurrence-free survival (HR 12.6, p <0.001) and cancer specific survival (HR 15.8, p <0.001). On multivariate analysis Ki-67 was an independent predictor of recurrence-free survival (HR 1.6, 95% CI 1.07-2.30, p=0.021) and cancer specific survival (HR 1.9, 95% CI 1.29-2.90, p=0.001). Ki-67 improved Harrell's C index from 0.66 to 0.70 (p <0.0001) for recurrence-free survival as well as cancer specific survival in our preoperative model, and from 0.81 to 0.82 (p=0.0018) for recurrence-free survival and 0.81 to 0.83 (p=0.005) for cancer specific survival in our postoperative model.

CONCLUSIONS

Ki-67 was validated as an independent predictor of recurrence-free survival and cancer specific survival in patients treated with extirpative surgery for high grade upper tract urothelial carcinoma in a large, multi-institutional cohort.

摘要

目的

我们验证Ki-67在高级别上尿路尿路上皮癌患者中的独立预测价值。

材料与方法

本研究纳入了国际上尿路尿路上皮癌协作组中475例接受高级别上尿路尿路上皮癌根治性手术的患者。对由该患者队列构成的组织芯片进行Ki-67免疫组化染色。以半定量方式评估Ki-67表达,当截断值为20%时认为其表达过高。进行多因素分析以评估肿瘤学结局的独立预测因素,并计算预测模型的Harrell's C指数。

结果

该队列的中位年龄为69.7岁,55.2%的患者为男性。25.9%的患者Ki-67表达过高。Ki-67表达过高与输尿管肿瘤位置、更高的pT分期、淋巴血管浸润、无蒂肿瘤结构、肿瘤坏死、伴发原位癌及区域淋巴结转移显著相关。在Kaplan-Meier分析中,Ki-67表达过高与无复发生存期较差(HR 12.6,p<0.001)及癌症特异性生存期较差(HR 15.8,p<0.001)相关。多因素分析显示,Ki-67是无复发生存期(HR 1.6,95%CI 1.07-2.30,p=0.021)和癌症特异性生存期(HR 1.9,95%CI 1.29-2.90,p=0.001)的独立预测因素。在我们的术前模型中,Ki-67使无复发生存期以及癌症特异性生存期的Harrell's C指数从0.66提高到0.70(p<0.0001),在术后模型中,使无复发生存期的Harrell's C指数从0.81提高到0.82(p=0.0018),癌症特异性生存期的Harrell's C指数从0.81提高到0.83(p=0.005)。

结论

在一个大型多机构队列中,Ki-67被验证为接受高级别上尿路尿路上皮癌根治性手术患者无复发生存期和癌症特异性生存期的独立预测因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验